Drugs / AK-01
AK-01
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04106219 | Jun 2020 → Apr 2022 overdue | neuroblastoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03955939 | Aug 2019 → May 2020 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03898791 | Jul 2019 → Jun 2020 | small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05017025 | Feb 2022 → Sep 2026 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03092934 | May 2017 → Apr 2020 | head and neck neoplasm, metastatic neoplasm, small cell lung carcinoma, triple-negative breast carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594367 ↗ |
| Known as | LY3295668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03955939 ↗ |
| Known as | LY3295668 Erbumine | “Drug: LY3295668 Erbumine” NCT04106219 ↗1“Drug: LY3295668 Erbumine” NCT03955939 ↗ |
| Action | Inhibit | “Aurora A Kinase Inhibitor LY3295668 Erbumine” NCT03955939 ↗ |
| Route | Oral | “administered orally” NCT03092934 ↗ |